News

Acceptance of telecare for MS varied with computer experience, disease duration

Publish date: June 25, 2013

 

AT THE CMSC/ACTRIMS ANNUAL MEETING

nmiller@frontlinemedcom.com
On Twitter @NaseemSMiller

Pages

Recommended Reading

Low weight may contribute to risk for natalizumab-induced PML
MDedge Neurology
Reports indicate dalfampridine may worsen trigeminal neuralgia
MDedge Neurology
Fingolimod slows MS brain atrophy within 6 months
MDedge Neurology
Efficacy and relapse frequency affect MS drug selection
MDedge Neurology
Multiple sclerosis research in 2013: opportunities and challenges
MDedge Neurology
In MS, 44% of excess mortality is potentially preventable
MDedge Neurology
Case series finds rituximab beneficial in secondary-progressive MS
MDedge Neurology
New and Noteworthy Information—May 2013
MDedge Neurology
PEGylated Interferon Beta-1a May Reduce Annualized Relapse Rate in Patients With MS
MDedge Neurology
Peginterferon beta-1a shows promise in relapsing-remitting MS
MDedge Neurology